Nasen (Zolpidem Tartrate)

Zolpidem Tartrate, the active ingredient in Nasen, is an imidazopyridine presented as an oral tablet for oral use. It is indicated for the short‑term treatment of insomnia in adults, helping to initiate and maintain sleep. The medication works by modulating central nervous system activity to promote sleep onset and continuity.

GNH USA supplies Nasen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, with reliable logistics.

Zolpidem Tartrate is a sedative/hypnotic that acts on the central nervous system to treat insomnia.

- Insomnia (short‑term): improves sleep onset and duration in adults. - Difficulty falling asleep: helps patients initiate sleep more quickly. - Frequent nighttime awakenings: reduces the number of awakenings and supports sleep continuity.

Zolpidem Tartrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Dizziness: light‑headed sensation or loss of balance. - Headache: mild to moderate pain in the head. - Nausea: feeling of stomach upset. - Dry mouth: reduced salivation. - Amnesia: short‑term memory impairment.

Serious or Rare Side Effects: - Complex sleep behaviors: activities such as sleepwalking, driving, or eating while not fully awake. - Allergic reactions: rash, swelling, or difficulty breathing indicating hypersensitivity.

When prescribing Zolpidem Tartrate, several safety considerations should be observed.

- Assess sleep history: confirm short‑term insomnia before use. - Avoid alcohol: concurrent use can increase sedation. - Use lowest effective dose: minimize risk of dependence. - Monitor for complex sleep behaviors: report unusual activities during sleep. - Avoid operating machinery: impairment may persist into the next day. - Store at room temperature: keep in original container, protect from moisture.

Zolpidem Tartrate can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Other CNS depressants (e.g., benzodiazepines, opioids): risk of profound sedation. - Alcohol: additive CNS depression and increased drowsiness. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise zolpidem plasma levels.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce zolpidem effectiveness. - Certain antidepressants (e.g., fluoxetine, sertraline): can increase sedative effect. - Antihistamines (e.g., diphenhydramine): may add to drowsiness.